产品说明书

Recilisib

Print
Chemical Structure| 334969-03-8 同义名 : ON 01210;EX-RAD
CAS号 : 334969-03-8
货号 : A803995
分子式 : C16H13ClO4S
纯度 : 99%+
分子量 : 336.79
MDL号 : MFCD07366276
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 35 mg/mL(103.92 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Recilisib, also known as ON 01210, is a radioprotective agent that activates AKT and PI3K activity in cells. Recilisib (up to 50 μM) shows a normal distribution of cells throughout the cell cycle, with a slight reduction in S phase cells at 50 μM. Continuous exposure to Recilisib (100 μM) does not lead to cell death. Treatment with Recilisib does not inhibit the colony-forming potential of human bone marrow cells. Recilisib provides dose-dependent protection to human bone marrow cells under all three doses of IR. It activates the phosphorylation of AKT and GSK3α/β in HFL cells. Recilisib increases the response of HFL-1 cells and mouse bone marrow cells to radiation exposure, thereby increasing PI3K activity. Treatment with Recilisib in combination with radiation therapy alters the MAPK signaling pathway[1].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.85mL

2.97mL

1.48mL

29.69mL

5.94mL

2.97mL
参考文献

[1]Kang AD, et al. ON01210.Na (Ex-RAD) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355.